Tharimmune Bets $540 Million on Blockchain-Powered Finance

Biotech firm Tharimmune has secured a significant $540 million funding round to bolster its cryptocurrency strategy. The company plans to acquire Canton Coin, the native token of the Canton Network, and expand its involvement in blockchain-based financial platforms. This investment underscores the growing intersection between traditional industries like biotech and the evolving landscape of digital assets and decentralized finance (DeFi).